OverviewSuggest Edit

Xencor is a clinical-stage biopharmaceutical company which focuses on discovery and development of engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The Company's product candidates include immune inhibitors for the treatment of autoimmune diseases, asthma and allergic diseases, acute myeloid leukemia, B-cell malignancies, non-Hodgkin lymphomas and chronic lymphocytic leukemia and multiple myeloma.

TypePublic
Founded1997
HQMonrovia, US
Websitexencor.com

Latest Updates

Employees (est.) (Dec 2018)156(+37%)
Job Openings19
Share Price (Jun 2019)$31

Key People/Management at Xencor

Bassil I. Dahiyat

Bassil I. Dahiyat

President & CEO
Edgardo Baracchini

Edgardo Baracchini

Chief Business Officer
John R. Desjarlais

John R. Desjarlais

Senior Vice President, Research and Chief Scientific Officer
John J. Kuch

John J. Kuch

Vice President, Finance
Paul Foster

Paul Foster

Senior Vice President, Chief Medical Officer
Show more

Xencor Office Locations

Xencor has offices in Monrovia and San Diego
Monrovia, US (HQ)
111 W Lemon Ave
San Diego, US
12770 High Bluff Dr #260
Show all (2)

Xencor Financials and Metrics

Xencor Revenue

USD

Net income (Q2, 2019)

(16.0m)

EBIT (Q2, 2019)

(19.6m)

Market capitalization (10-Jun-2019)

1.7b

Closing stock price (10-Jun-2019)

31.0

Cash (30-Jun-2019)

32.6m
Xencor's current market capitalization is $1.7 b.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

General and administrative expense

12.0m13.1m17.5m22.5m

R&D expense

34.1m51.9m71.8m97.5m

Operating expense total

46.1m65.0m89.3m120.0m

EBIT

(18.3m)22.5m(53.6m)(79.4m)
Quarterly
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Cash

12.6m14.5m16.5m26.2m

Accounts Receivable

44.0k8.6m1.1m10.2m

Current Assets

97.7m141.7m230.9m315.7m

PP&E

2.3m3.1m7.1m11.8m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(17.6m)23.6m(48.9m)(70.4m)

Depreciation and Amortization

1.1m1.5m2.0m3.3m

Accounts Payable

4.7m(2.5m)3.0m(3.1m)

Cash From Operating Activities

26.7m94.6m(33.7m)(79.8m)
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q1, 2019Q2, 2019

Net Income

(15.3m)(25.3m)(6.4m)40.8m32.7m(14.6m)(21.5m)(37.1m)(29.5m)(55.4m)80.0m64.0m

Depreciation and Amortization

494.0k768.0k282.0k628.0k999.0k410.0k864.0k1.4m730.0k1.6m996.0k2.0m

Accounts Payable

1.4m3.4m(2.1m)1.3m934.0k395.0k3.5m2.7m1.7m(2.0m)1.7m5.2m

Cash From Operating Activities

(9.0m)30.5m(14.3m)(23.7m)110.4m(10.7m)(23.5m)(27.0m)(24.2m)(52.7m)(18.7m)90.4m
USDY, 2019

Financial Leverage

1.1 x
Show all financial metrics

Xencor Online and Social Media Presence

Embed Graph

Xencor News and Updates

Xencor Announces the Planned Retirement of Chief Medical Officer Paul Foster, M.D.

Dr. Foster’s career spans 35 years in academic research, medical practice and industry leadership. For ten years, he has led Xencor’s clinical development strategy, as both chief medical officer and as a consultant in a substantially similar capacity. Xencor has initiated an executive search for a s…

Xencor Reports Fourth Quarter and Full Year 2018 Financial Results

MONROVIA, Calif., Feb. 25, 2019 /PRNewswire/ -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today reported financial results for the...

Xencor to Develop and Commercialize Novel IL-15 Immune Activating Cytokines with Genentech

MONROVIA, Calif., Feb. 5, 2019 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic disease, and cancer, today announced it has entered into a...

Xencor Presents Initial Data from Phase 1 Study of XmAb®14045 in Acute Myeloid Leukemia at the 2018 ASH Annual Meeting

MONROVIA, Calif., Dec. 3, 2018 /PRNewswire/ -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today announced initial data from its ongoing Phase 1...

Xencor to Present at 30th Annual Piper Jaffray Healthcare Conference

MONROVIA, Calif., Nov. 20, 2018 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil Dahiyat,...

Xencor Appoints Ellen G. Feigal, M.D., to Board of Directors

MONROVIA, Calif., Nov. 8, 2018 /PRNewswire/ -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced the appointment of Ellen G....
Show more

Xencor Blogs

Xencor Reports Second Quarter 2019 Financial Results

Xencor Reports Second Quarter 2019 Financial Results ryan.manuel Tue, 08/06/2019 - 16:01 Xencor Reports Second Quarter 2019 Financial Results Aug 06, 2019 This release is a backfill from a News Wire Earnings -- Management to Host Conf…

Xencor to Host Second Quarter 2019 Financial Results Webcast and Conference Call on August 6, 2019

MONROVIA, Calif. --(BUSINESS WIRE)--Jul. 30, 2019-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that it will release second quarter

Xencor Doses First Patient in Phase 1 Study of XmAb®22841 for the Treatment of Patients with Advanced Solid Tumors

— XmAb22841, a CTLA-4 x LAG-3 bispecific antibody, is Xencor’s third tumor microenvironment (TME) activator to enter clinical development — — Phase 1 study to explore the combination of XmAb22841 with pembrolizumab, an anti-PD-1 immunotherapy, to create triple checkpoint blockade — MONROVIA, Calif.

Xencor Appoints Jeremy Grunstein, Ph.D., as Vice President, Business Development

Xencor Appoints Jeremy Grunstein, Ph.D., as Vice President, Business Development Content Import Thu, 05/23/2019 - 08:02 Xencor Appoints Jeremy Grunstein, Ph.D., as Vice President, Business Development May 23, 2019 This release is a backfill from a News Wire …

Xencor and Astellas Enter Collaboration for Novel Bispecific Antibody Program

-- Partners to Generate Novel Bispecific Antibodies Directed Toward an Anti-tumor Target Identified by Astellas -- -- Astellas to Receive Exclusive Worldwide License to Potential Drug Candidates -- MONROVIA, Calif. --(BUSINESS WIRE)--Apr. 2, 2019-- Xencor, Inc.

Xencor Announces Closing of Research Collaboration and License Agreement with Genentech

MONROVIA, Calif. --(BUSINESS WIRE)--Mar. 8, 2019-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today announced the closing of its research
Show more

Xencor Frequently Asked Questions

  • When was Xencor founded?

    Xencor was founded in 1997.

  • Who are Xencor key executives?

    Xencor's key executives are Bassil I. Dahiyat, Edgardo Baracchini and John R. Desjarlais.

  • How many employees does Xencor have?

    Xencor has 156 employees.

  • Who are Xencor competitors?

    Competitors of Xencor include ASLAN Pharmaceuticals, Shanghai Henlius Biotech and Corcept Therapeutics.

  • Where is Xencor headquarters?

    Xencor headquarters is located at 111 W Lemon Ave, Monrovia.

  • Where are Xencor offices?

    Xencor has offices in Monrovia and San Diego.

  • How many offices does Xencor have?

    Xencor has 2 offices.